Capricor Therapeutics Announces Development of Serology Test to Confirm Activity of SARS-CoV-2 Vaccines
February 01, 2021 09:15 ET
|
Capricor Therapeutics
-Technology Licensed from Johns Hopkins University- -Patient Data Demonstrates Validity of Novel Imaging-Based Approach Furthering Capricor’s Platform Advancement- LOS ANGELES, Feb. 01,...
Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes
January 19, 2021 09:15 ET
|
Capricor Therapeutics
-Enhanced Signaling Pathways Show Increased Potency Through Expression of MicroRNAs- -Publication Further Supports Capricor’s Exosome Platform Advancement- LOS ANGELES, Jan. 19, 2021 (GLOBE...
Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications
January 12, 2021 09:05 ET
|
Capricor Therapeutics
—Capricor to leverage Lonza’s expertise in technology transfer and development of cellular therapies to take CAP-1002 through potential product launch and commercial supply— —The collaboration aims...
Capricor Therapeutics Announces DSMB Recommendation to Continue Phase II INSPIRE Trial for Severe COVID-19 Patients
December 29, 2020 09:15 ET
|
Capricor Therapeutics
LOS ANGELES, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
Capricor Therapeutics Commences Dosing Patients in Phase 2 Trial of CAP-1002 in Patients with Severe COVID-19
November 24, 2020 07:30 ET
|
Capricor Therapeutics
- Data Expected Second Quarter 2021 - - The INSPIRE Trial Is Designed to Assess the Ability of CAP-1002 to Modulate the Cytokine Storm Associated With Severe COVID-19 - LOS ANGELES, Nov. ...
Capricor Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 12, 2020 16:01 ET
|
Capricor Therapeutics
Exosome Platform Technology-Announced Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19--Novel Vaccine Induced Long-Lasting Immunity to Multiple SARS-CoV-2...
Capricor Therapeutics Announces Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19
November 09, 2020 09:15 ET
|
Capricor Therapeutics
Potential Vaccine Candidate Employs Novel Exosome-Based mRNA Delivery Platform that Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins Capricor Scheduling Pre-IND Meeting with FDA...
Capricor Therapeutics to Present Third Quarter 2020 Financial Results and Recent Corporate Update on November 12
November 05, 2020 09:00 ET
|
Capricor Therapeutics
LOS ANGELES, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based...
Capricor Therapeutics to Present Results from the HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at the International World Muscle Society Virtual Congress 2020
September 23, 2020 09:25 ET
|
Capricor Therapeutics
--Final 12-Month Results from Phase II Trial to be Presented on October 1-- LOS ANGELES, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage...
Capricor Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference
September 10, 2020 09:15 ET
|
Capricor Therapeutics
LOS ANGELES, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and...